← LeaderboardsInvestigatorsiAttributed = a PI's even-split share of each grant — a $1M grant with 2 PIs counts $500K each.
Aaron Diamond Aids Research Center
New York, NY
$115,200,319
Total funding
80
Grants
Funding over time
peak $8.1M · FY2005–19$10M$7.5M$5M$2.5M$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
Funding mix
By agency
NIH$115,200,319 · 80
By mechanism
R01$77,174,970 · 38
U01$10,131,316 · 1
R37$8,031,725 · 3
R21$7,084,839 · 16
DP1$4,401,050 · 1
R56$3,379,996 · 5
Investigators at Aaron Diamond Aids Research Center
InvestigatorsiAttributed = a PI's even-split share of each grant — a $1M grant with 2 PIs counts $500K each.
Exposure= the full size of every grant they're on ($1M each).
Rising Stars
First grant in the last 5 yrs
Not enough data
Emerging Leaders
6–10 yrs in
Largest grants
Understanding and Altering the Virologic Setpoint$1,710,399
U01 · FY2005 · AI
Understanding and Altering the Virologic Setpoint$1,710,399
U01 · FY2006 · AI
Understanding and Altering the Virologic Setpoint$1,645,592
U01 · FY2004 · AI
A preclinical assessment of monthly intramuscular GSK1265744, an InSTI, as PrEP$1,591,251
R01 · FY2013 · AI
Understanding and Altering the Virologic Setpoint$1,582,060
U01 · FY2003 · AI
Understanding and Altering the Virologic Setpoint$1,427,737
U01 · FY2002 · AI
Assessment of vaccine/microbicide combination efficacy in the macaque model$1,280,247
R01 · FY2009 · AI
R5 SHIV/Macaque Models for the Evaluation of T and B Cell-Based HIV-1 Vaccines$1,104,451
R01 · FY2012 · AI
VIRAL AND IMMUNE CONSEQUENCES OF EARLY HIV1 THERAPY$1,034,303
U01 · FY2000 · AI
VIRAL AND IMMUNE CONSEQUENCES OF EARLY HIV1 THERAPY$1,020,826
U01 · FY2001 · AI
Correlates and Consequences of Increased Immune Activation in HIV + and - IDUs$1,011,463
R01 · FY2012 · DA
Correlates and Consequences of Increased Immune Activation in HIV + and - IDUs$944,831
R01 · FY2014 · DA
Bispecific and Trispecific Anti-Env Antibodies for Eliminating HIV Reservoir Cells$930,446
R01 · FY2017 · AI
Correlates and Consequences of Increased Immune Activation in HIV + and - IDUs$921,636
R01 · FY2013 · DA
Correlates and Consequences of Increased Immune Activation in HIV + and - IDUs$920,449
R01 · FY2016 · DA
Correlates and Consequences of Increased Immune Activation in HIV + and - IDUs$916,984
R01 · FY2015 · DA
Bispecific and Trispecific Anti-Env Antibodies for Eliminating HIV Reservoir Cells$910,463
R01 · FY2018 · AI
R5 SHIV/Macaque Models for the Evaluation of T and B Cell-Based HIV-1 Vaccines$897,508
R01 · FY2009 · AI
Monthly Antiretroviral Therapy Using Multispecific HIV Neutralizing Antibodies$890,000
DP1 · FY2012 · DA
Monthly Antiretroviral Therapy Using Multispecific HIV Neutralizing Antibodies$890,000
DP1 · FY2011 · DA